ProQR Therapeutics NV (PRQR)
2.02
+0.02
(+1.00%)
USD |
NASDAQ |
May 10, 13:38
ProQR Therapeutics Revenue (Quarterly): 3.537M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.537M |
| September 30, 2023 | 1.492M |
| June 30, 2023 | 1.314M |
| March 31, 2023 | 0.7035M |
| December 31, 2022 | 0.7362M |
| September 30, 2022 | 0.82M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.9906M |
| March 31, 2022 | 1.268M |
| December 31, 2021 | 0.2516M |
| September 30, 2021 | 1.028M |
| June 30, 2021 | 0.2929M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.2516M
Minimum
Dec 2021
3.537M
Maximum
Dec 2023
1.130M
Average
0.9906M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| uniQure NV | 6.689M |
| Merus NV | 8.939M |
| argenx SE | 406.84M |
| Pharming Group | 81.22M |
| Pharvaris NV | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.905M |
| Total Expenses (Quarterly) | 13.44M |
| EPS Diluted (Quarterly) | -0.0754 |
| Enterprise Value | 35.99M |
| Profit Margin (Quarterly) | -167.0% |
| Earnings Yield | -18.75% |
| Normalized Earnings Yield | -21.35 |